Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.

ABSTRACT:

Background & aims

CD44s is a surface marker of tumor-initiating cells (TICs); high tumor levels correlate with metastasis and recurrence, as well as poor outcomes for patients. Monoclonal antibodies against CD44s might eliminate TICs with minimal toxicity. This strategy is unclear for treatment of pancreatic cancer, and little is known about how anti-CD44s affect pancreatic cancer initiation or recurrence after radiotherapy.

Methods

One hundred ninety-two pairs of human pancreatic adenocarcinoma and adjacent nontumor pancreatic tissues were collected from patients undergoing surgery. We measured CD44s levels in tissue samples and pancreatic cancer cell lines by immunohistochemistry, real-time polymerase chain reaction, and immunoblot; levels were correlated with patient surv

SUBMITTER: Li L 

PROVIDER: S-EPMC3982149 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature